Treatment Modalities LC Flashcards
(225 cards)
drugs that deplete or inhibit proliferation of MDSCs
Liposomal clodronate
Gemcitabine
5-FU
Sunitinib
Docetaxel
Cox 2 inhibitor (SC58236)
KIT-specific Ab
25-Hydroxyvitamin D
CXCR2 antagonist (S-265610)
CXCR4 antagonist (AMD3100)
PROK2-specific Ab
drugs that promote maturation of MDSCs
Zoledronate
ATRA
Docetaxel
Sunitinib
Decitabine
Activated NKT cells
VSSP vaccine
drugs that inhibit recruitment of MDSCs
cFMS kinase inhibitor (GW2580)
NSAIDs
drugs that block interaction of MDSCs
Anti-CD40 Ab
Anti-PD-1/PD-L1 Ab
drugs that block function of MDSCs
Nitroaspirin
Arginase 1 inhibitor (NOHA)
Triterpenoid
Sildenafil
drugs that cause pulmonary fibrosis
Tanovea, bleomycin, gemcitabine, EGFR-directed therapies, MTOR inhibitors, immune checkpoint inhibitors, methotrexate
indications for bone marrow transplant
Hematopoietic Disorders:
Acute leukemias (e.g., acute lymphoblastic leukemia, acute myeloid leukemia) with a high risk of relapse or refractory disease.
Aplastic anemia, where the bone marrow fails to produce adequate blood cells.
Immune-mediated disorders affecting bone marrow function.
lymphoma
risks of bone marrow transplant
Graft-versus-Host Disease (GVHD): A major risk of BMT, where donor immune cells attack the recipient’s tissues, leading to severe inflammation and organ damage.
Infection: Immunosuppression post-transplantation increases the risk of infections, including bacterial, fungal, and viral infections.
Graft Failure: The transplanted bone marrow may fail to engraft and produce sufficient blood cells.
Toxicity: Conditioning regimens and immunosuppressive drugs used in BMT can cause systemic toxicity, including gastrointestinal, hepatic, and renal toxicity.
Secondary Malignancies: Long-term immunosuppression increases the risk of secondary malignancies, including lymphoma and other cancers.
graft vs host disease
allogeneic stem cell transplantation - ~33% of patients in one paper 3/9 dogs
Donor T cells present in the graft recognize alloantigens (foreign antigens) on recipient tissues, such as major histocompatibility complex (MHC) molecules. leads to the activation and expansion of donor T cells.
Activated donor T cells differentiate into effector T cells, including CD4+ T helper cells and CD8+ cytotoxic T cells.
Activated T cells secrete pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6), and interferon-gamma (IFN-γ).
These cytokines contribute to tissue inflammation, damage, and recruitment of additional immune cells.
Effector T cells attack and damage recipient tissues, primarily the skin, gastrointestinal tract, and liver.
Skin manifestations include erythematous rash, blistering, and desquamation.
Gastrointestinal manifestations include diarrhea, abdominal pain, and mucosal damage.
Liver involvement can lead to hepatomegaly, jaundice, and hepatic dysfunction.
graft vs host disease acute vs chronic
Acute GVHD typically occurs within the first 100 days after transplantation and is characterized by a rapid onset of symptoms.
Chronic GVHD develops later, usually after day 100 post-transplant, and can persist for months to years. It often resembles autoimmune disorders and can affect multiple organs.
Direct Cytotoxicity: Effector T cells directly attack and kill recipient cells through cytotoxic mechanisms, including perforin and granzyme-mediated apoptosis.
Indirect Pathways: Effector T cells activate macrophages and other immune cells, leading to tissue inflammation and damage.
Antibody-Mediated Damage: B cells activated by donor T cells produce antibodies against recipient tissues, contributing to tissue damage.
prevention and treatment of graft vs host disease
Prevention and Treatment:
GVHD prophylaxis strategies aim to suppress donor T cell activation and function while preserving graft-versus-tumor effects.
Treatment options for established GVHD include immunosuppressive drugs such as cyclophosphamide, corticosteroids, calcineurin inhibitors (e.g., cyclosporine, tacrolimus), and anti-T cell antibodies (e.g., anti-thymocyte globulin).
Severe cases of GVHD may require additional therapies, such as extracorporeal photopheresis or mesenchymal stem cell therapy, to modulate immune responses and reduce tissue damage.
limitations of BMT
Donor Availability: Finding an appropriate donor (allogeneic) or preparing the recipient as its own donor (autologous) can be challenging.
Cost: BMT is an expensive procedure, including pre-transplant workup, conditioning regimens, transplantation, post-transplant care, and potential complications.
Specialized Facilities: BMT requires access to specialized facilities and expertise, including hematologists/oncologists, aphoesis, and specialized laboratories.
Intrinsic Limitations: Some conditions may not be suitable for BMT due to poor prognosis or lack of response to prior chemo treatment
Success Rates of BMT
Success rates for allogeneic BMT in dogs ~89%
Reported success rates for autologous BMT in dogs with lymphoma range from 33 - 40%
allogeneic bmt can cure ~50% more dogs than those treated with autologous
Survival Time: Dogs that successfully undergo BMT may achieve long-term remission or cure, with survival times ranging from months to several years.
Quality of Life: Dogs that undergo successful BMT can regain a good quality of life, with resolution of clinical signs associated with the underlying disease.
Complications: Even in successful cases, dogs may experience complications such as GVHD, infections, and long-term organ toxicities.
aphoresis
Blood Collection: Apheresis begins by drawing blood
Separation Process: The collected blood is then processed through a machine called an apheresis machine. This machine separates the blood into its individual components, such as red blood cells, white blood cells, platelets, and plasma.
Targeted Component Removal: Depending on the purpose of the procedure, specific components of the blood may be removed, such as:
White Blood Cells: Used for patients with certain immune disorders or to reduce the risk of organ rejection in transplant recipients.
Return of Remaining Blood: After the targeted component is removed, the remaining blood components are returned to the body
Filgrastim (G-CSF)
Granulocyte colony-stimulating factor (G-CSF) is used to stimulate the production of neutrophils and accelerate bone marrow recovery after transplantation.
Neupogen
human may not work in dogs
Anti-Thymocyte Globulin (ATG):
ATG is a polyclonal antibody preparation derived from animals (e.g., horse or rabbit) that targets and depletes T cells. It is used as part of the conditioning regimen before BMT to reduce the risk of GVHD
how does Cyclophosphamide work as an immunosuppressant in BMT
inhibiting the function of T and B lymphocytes. only cyclophosphamide and methotrexate can induce apoptosis of alloantigen-activated human T cells. Another unique cyclophosphamide mode of action is upregulation of CD95 expression, which leads to activation-induced apoptosis within 6 days, further preventing T-cell activation
By suppressing the immune system, cyclophosphamide helps prevent rejection of the transplanted bone marrow and reduces the risk of graft-versus-host disease (GVHD).
used to eliminate any remaining cancer cells in the bone marrow and peripheral blood and prevent gvhd.
is often used in combination with other chemotherapy drugs or radiation therapy to maximize its effectiveness in conditioning the recipient
cyclophosphamide dose for BMT
Cyclophosphamide is often administered at high doses, typically ranging from 200 to 400 mg/m^2.
The dose may be given as a single dose or divided into multiple doses over several days.
Some protocols may use higher doses of up to 600 mg/m^2, particularly in aggressive lymphoma protocols.
radiation for BMT
Fractionated total body irradiation involves dividing the total dose into multiple smaller fractions delivered over several days.
Single dose total body irradiation delivers the entire radiation dose in one session.
Typical doses for single dose TBI in dogs range from 8 to 12 Gray (Gy).
Mushroom-Derived Products evidence
Certain mushroom-derived products, such as polysaccharopeptide (PSP) from Coriolus versicolor ( turkey tail) and lentinan from Shiitake mushrooms, have been studied for their potential anticancer properties in both humans and animals.
Sulforaphanes use
Evidence: Sulforaphanes are bioactive compounds found in cruciferous vegetables like broccoli and cauliflower, known for their antioxidant and anti-inflammatory properties.
Effectiveness: Limited studies have investigated the use of sulforaphanes in dogs and cats with cancer. Some research suggests potential anticancer effects by modulating signaling pathways involved in tumor growth and progression.
Yunnan Baiyao:
Evidence: Yunnan Baiyao is a traditional Chinese herbal medicine used for its hemostatic and anti-inflammatory properties.
Hepatoprotectants:
Hepatoprotectants, such as S-adenosylmethionine (SAMe) and milk thistle (silymarin), are commonly used to support liver function in dogs and cats with cancer, especially those undergoing chemotherapy.
Herbal Supplements:
Evidence: Various herbal supplements, such as astragalus, turmeric, and green tea extract, have been studied for their potential anticancer effects in animals.
Effectiveness: While some preclinical studies suggest possible benefits, clinical evidence in dogs and cats with cancer is limited and often inconclusive.